At the news
? MIXEDIMPACT 7/10 PRESS-RELEASE filed May 6, 2026 at 08:00 ET
Taysha reported Q1 2026 EPS of -$0.12 (GAAP), wider than the -$0.08 consensus, with zero revenue vs $2.3M a year ago. The stock will move on the FDA's reaffirmed alignment for a BLA submission for TSHA-102 based on the REVEAL pivotal trial's 6-month interim analysis, with dosing completion expected in Q2 2026.
- Q1 2026 GAAP net loss per share -$0.12 vs -$0.08 consensus (miss of 50%)
- Revenue was $0, down from $2.3M in Q1 2025
- Net loss widened to $42.4M from $21.5M YoY, driven by $33.8M R&D spend (up 117%)
- Cash and equivalents $276.6M, expected to fund operations into 2028
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access